Generic Name and Formulations:
Aflibercept 40mg/mL; soln for oph intravitreal inj; preservative-free.
Indications for EYLEA:
Neovascular (wet) age-related macular degeneration (AMD). Macular edema following retinal vein occlusion (RVO). Diabetic macular edema (DME).
Give by intravitreal injection. AMD: 2mg (0.05mL) once every 4 weeks (monthly) for the 1st 3 months, followed by 2mg (0.05mL) once every 8 weeks. RVO: 2mg (0.05mL) once every 4 weeks (monthly). DME: 2mg (0.05mL) once every 4 weeks (monthly) for the 1st 5 injections, followed by 2mg (0.05mL) once every 8 weeks (2 months).
Recombinant fusion protein (human VEGF inhibitor + human IgG1).
Ocular or periocular infections. Active intraocular inflammation.
Potential risk of arterial thromboembolic events (eg, nonfatal stroke or MI, vascular death). Monitor for endophthalmitis and retinal detachments during the week following injection. Monitor intraocular pressure and perfusion of optic nerve head after injection. Pregnancy (Cat.C). Nursing mothers: not recommended.
Conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, increased intraocular pressure, conjunctival hyperemia, corneal erosion, inj site pain, foreign body sensation in eye.
Vial (for single eye use)—1 (w. needles + syringe)
- 0.05ml of 2mg/0.05ml vials (Qty:1)
- appx. price $1896.00
- McDonald's and the Microbiome: What Effect Does Junk Food Have on Gut Bacteria?
- When the Doctor is Depressed: One Clinician Tells His Story
- Most Distinctive Causes of Death Mapped by U.S. State
- Spice + Statin Likely Culprit in Patient with Acute Hepatitis
- First Non-Surgical Tx for "Double Chin" Gains FDA Approval